• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

从对索托拉西布有出色反应的G12C突变肺腺癌发生的新发小细胞肺癌转化：一例报告

De Novo SCLC Transformation From G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report.

作者信息

Ito Takanori, Oi Issei, Saito Zentaro, Imakita Takuma, Kanai Osamu, Fujita Kohei, Tachibana Hiromasa, Moriyoshi Koki, Mio Tadashi

机构信息

Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Division of Pathology, National Hospital Organisation Kyoto Medical Center, Kyoto, Japan.

出版信息

JTO Clin Res Rep. 2023 Mar 29;4(5):100510. doi: 10.1016/j.jtocrr.2023.100510. eCollection 2023 May.

DOI:10.1016/j.jtocrr.2023.100510
PMID:37131995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10149245/
Abstract

The transformation to SCLC is a known mechanism of resistance against molecularly targeted therapies. This study reports a patient with untreated lung adenocarcinoma, characterized by a G12C mutation, which transformed into SCLC before treatment. Both the adenocarcinoma and SCLC components were responsive to sotorasib.

摘要

向小细胞肺癌（SCLC）的转化是一种已知的对分子靶向治疗产生耐药性的机制。本研究报告了一名未经治疗的肺腺癌患者，其特征为存在G12C突变，在治疗前转化为SCLC。腺癌和SCLC成分对索托拉西布均有反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/b457eb58788b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/778e5d03eaf2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/c56865d9244a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/b457eb58788b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/778e5d03eaf2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/c56865d9244a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0208/10149245/b457eb58788b/gr3.jpg

相似文献

1
De Novo SCLC Transformation From G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report.从对索托拉西布有出色反应的G12C突变肺腺癌发生的新发小细胞肺癌转化：一例报告
JTO Clin Res Rep. 2023 Mar 29;4(5):100510. doi: 10.1016/j.jtocrr.2023.100510. eCollection 2023 May.
2
Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.索托拉西布作为晚期KRAS G12C突变型非小细胞肺癌的一线治疗：病例报告
Case Rep Oncol. 2023 Mar 30;16(1):177-181. doi: 10.1159/000529828. eCollection 2023 Jan-Dec.
3
Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.KRAS G12C抑制剂索托拉西布用于非小细胞肺癌一线治疗的混合反应：简要报告
Clin Case Rep. 2024 May 24;12(6):e8866. doi: 10.1002/ccr3.8866. eCollection 2024 Jun.
4
Remarkable Intracranial Response to Sotorasib in a Patient With -Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report.一例携带KRAS G12C突变的肺腺癌伴未经治疗脑转移患者对索托拉西布的显著颅内反应：病例报告
JTO Clin Res Rep. 2022 Nov 6;3(12):100428. doi: 10.1016/j.jtocrr.2022.100428. eCollection 2022 Dec.
5
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.索托拉西布：一种用于治疗KRAS G12C突变的非小细胞肺癌的药物。
Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573.
6
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.索托拉西布在伴有突变型肺腺癌和未经治疗的活动性脑转移的患者中显示出颅内活性。
Case Rep Oncol. 2022 Aug 26;15(2):720-725. doi: 10.1159/000525341. eCollection 2022 May-Aug.
7
BCL-X PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS-mutated cancers.BCL-X PROTAC降解剂DT2216在KRAS突变癌症的临床前模型中与索托拉西布协同作用。
J Hematol Oncol. 2022 Mar 9;15(1):23. doi: 10.1186/s13045-022-01241-3.
8
KRAS Inhibitor Resistance in -Amplified Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.KRAS 抑制剂耐药性在 -扩增非小细胞肺癌中由 RAS 和非 RAS 介导的细胞信号转导机制诱导。
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7.
9
CodeBreaK 200: Sotorasib (AMG510) Has Broken the + NSCLC Enigma Code.CodeBreaK 200：索托拉西布（AMG510）破解了KRAS G12C突变型非小细胞肺癌之谜。
Lung Cancer (Auckl). 2023 Apr 20;14:31-39. doi: 10.2147/LCTT.S403614. eCollection 2023.
10
Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.从“来世”归来？索托拉西布治疗晚期KRAS突变肺癌：一例病例报告。
World J Clin Cases. 2024 Sep 6;12(25):5805-5813. doi: 10.12998/wjcc.v12.i25.5805.

引用本文的文献

1
Heterogeneity and co-occurrence of resistance mechanisms in EGFR-TKI-induced NSCLC to SCLC transformation: a case report.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）诱导的非小细胞肺癌向小细胞肺癌转化中耐药机制的异质性与共现：一例报告
AME Case Rep. 2025 Jun 18;9:85. doi: 10.21037/acr-24-67. eCollection 2025.
2
Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis.ALK高表达在小细胞肺癌中的预后意义：一项9年队列分析
Front Oncol. 2025 Mar 25;15:1530339. doi: 10.3389/fonc.2025.1530339. eCollection 2025.
3
CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma.

本文引用的文献

1
Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.视网膜母细胞瘤表达和 CDK4/6 抑制剂在小细胞肺癌中的靶向作用。
Mol Cancer Ther. 2023 Feb 1;22(2):264-273. doi: 10.1158/1535-7163.MCT-22-0365.
2
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.EGFR/ALK 野生型或 TKI 初治的非小细胞肺癌的神经内分泌转化：一种被低估的现象。
Lung Cancer. 2022 Jul;169:22-30. doi: 10.1016/j.lungcan.2022.05.002. Epub 2022 May 17.
3
Clinicopathologic and molecular characteristics of -mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.
CRACD 缺失诱导肺腺癌神经内分泌细胞可塑性。
Cell Rep. 2024 Jun 25;43(6):114286. doi: 10.1016/j.celrep.2024.114286. Epub 2024 May 25.
经TKI治疗后转化为小细胞肺癌的-mutant肺腺癌的临床病理及分子特征。 （注：原文中“-mutant”表述不完整，可能影响准确理解）
Transl Lung Cancer Res. 2022 Mar;11(3):452-461. doi: 10.21037/tlcr-21-665.
4
-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report.- 奥希替尼成功治疗自发转化为小细胞肺癌和伴有神经内分泌分化腺癌的突变型肺腺癌：病例报告
JTO Clin Res Rep. 2021 Dec 4;3(1):100264. doi: 10.1016/j.jtocrr.2021.100264. eCollection 2022 Jan.
5
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.同时存在 RB1 和 TP53 改变的 EGFR 突变型肺癌具有组织学转化和临床结局不良的风险。
J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.
6
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.表皮生长因子受体突变型腺癌转化为小细胞肺癌和其他神经内分泌癌：临床结局。
J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.
7
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.联合型小细胞肺癌与非小细胞肺癌不同组织学成分的临床病理与基因组学比较。
Lung Cancer. 2018 Nov;125:282-290. doi: 10.1016/j.lungcan.2018.10.006. Epub 2018 Oct 9.
8
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.非小细胞肺癌向小细胞肺癌的转变：分子驱动因素及起源细胞
Lancet Oncol. 2015 Apr;16(4):e165-72. doi: 10.1016/S1470-2045(14)71180-5.
9
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.对表皮生长因子受体（EGFR）突变的耐药性肺腺癌转化为小细胞肺癌过程中的RB基因缺失。
Nat Commun. 2015 Mar 11;6:6377. doi: 10.1038/ncomms7377.
10
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.全面的基因组分析确定 SOX2 是小细胞肺癌中经常扩增的基因。
Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.